AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9923552 — intervention group
Group type: COMPARATOR
Intervention: Oral LV 30 mg plus UFT 200 mg
Number of subjects: 19
Study 8635038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) administered subcutaneously at a dose of 150 U/kg three times per week for 6 weeks; in nonresponders, the dose was doubled for the subsequent 6 weeks.
Number of subjects: 102
Study 8635038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 102
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction ALG
Number of subjects: 110
Study 1871856 — intervention group
Group type: COMPARATOR
Intervention: Continuous IV CyA
Number of subjects: 110
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA monotherapy
Number of subjects: 110
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: First rejection
Number of subjects: 110
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: Second rejection
Number of subjects: 110
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: Third rejection
Number of subjects: 110
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejections after 30 days
Number of subjects: 110
Study 1871856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejections after 90 days
Number of subjects: 110
Study 6352600 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin at 18 g/day for a mean of 13 days
Number of subjects: 42
Study 6352600 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin at 180 mg/day for a mean of 11 days
Number of subjects: 42
Study 30277424 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchored to a four-times-daily treatment regimen
Number of subjects: 100
Study 30277424 — intervention group
Group type: COMPARATOR
Intervention: Not anchored
Number of subjects: 100
Study 29735964 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion therapy combined with calcium carbonate D3
Number of subjects: 63
Study 29735964 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate D3 only (Control)
Number of subjects: 63
Study 27031702 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV illness episodes during pregnancy
Number of subjects: 3693
Study 27031702 — intervention group
Group type: COMPARATOR
Intervention: Women without RSV during pregnancy
Number of subjects: 3693
Study 27031702 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum RSV infection in mothers
Number of subjects: 3693
Study 25112865 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 20mg/kg/day
Number of subjects: 72
Study 25112865 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 40mg/kg/day
Number of subjects: 72
Study 25112865 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 60mg/kg/day
Number of subjects: 72
Study 25112865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25112865 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 20mg/kg/day (subgroup analysis)
Number of subjects: 72
Study 22747998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention teams with priority flags for intensification added to the registry database.
Number of subjects: 0
Study 22747998 — intervention group
Group type: COMPARATOR
Intervention: Control teams using the same database without the new information.
Number of subjects: 0
Study 20825758 — intervention group
Group type: COMPARATOR
Intervention: Bipolar TURP
Number of subjects: 2245
Study 20825758 — intervention group
Group type: COMPARATOR
Intervention: Bipolar TUVP
Number of subjects: 2245
Study 20825758 — intervention group
Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 2245
Study 20825758 — intervention group
Group type: COMPARATOR
Intervention: KTP laser vaporisation
Number of subjects: 2245
Study 17609305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative target-absorbed dose of 200 Gy (n = 78)
Number of subjects: 177
Study 17609305 — intervention group
Group type: COMPARATOR
Intervention: Nonablative doses of 100 or 120 Gy (n = 99)
Number of subjects: 177
Study 15640479 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg isoflavones/d
Number of subjects: 202
Study 15640479 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (placebo)
Number of subjects: 202
Study 15640479 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg isoflavones/d (in equol producers)
Number of subjects: 202
Study 15640479 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg isoflavones/d (in equol nonproducers)
Number of subjects: 202
Study 11906798 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day buprenorphine
Number of subjects: 330
Study 11906798 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day buprenorphine
Number of subjects: 330
Study 11906798 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/day buprenorphine
Number of subjects: 330
Study 9950598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cyclosporin A (CsA) drops for 3 months
Number of subjects: 8
Study 9950598 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops for 3 months
Number of subjects: 8
Study 8789590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen (1 mg orally, administered 5 hours before exercise)
Number of subjects: 8
Study 8789590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8789590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 8
Study 2105371 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 49
Study 2105371 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 49
Study 2105371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Genuine and Sham)
Number of subjects: 49
Study 41413 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyl-p-tyrosine (AMPT)
Number of subjects: 0
Study 41413 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 0
Study 41413 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31415381 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingzhong (TDF) 300mg once daily for 48 weeks
Number of subjects: 330
Study 31415381 — intervention group
Group type: COMPARATOR
Intervention: Viread (TDF) 300mg once daily for 48 weeks
Number of subjects: 330
Study 27741030 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 219
Study 27741030 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 219
Study 26044169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035 doses <100 ng
Number of subjects: 0
Study 26044169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035 at 20 ng
Number of subjects: 0
Study 26044169 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat intranasal GSK2245035 administration
Number of subjects: 0
Study 26044169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035
Number of subjects: 0
Study 26044169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23432466 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-sparing regimens (e.g., raltegravir plus darunavir/ritonavir)
Number of subjects: 689
Study 23432466 — intervention group
Group type: COMPARATOR
Intervention: NRTI-based regimens (e.g., tenofovir DF/emtricitabine plus darunavir/ritonavir)
Number of subjects: 689
Study 22108937 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 400 μmol l(‐1) in antegrade cardioplegia
Number of subjects: 80
Study 22108937 — intervention group
Group type: COMPARATOR
Intervention: Placebo in antegrade cardioplegia
Number of subjects: 80
Study 22108937 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 400 μmol l(‐1) in retrograde cardioplegia
Number of subjects: 80
Study 22108937 — intervention group
Group type: COMPARATOR
Intervention: Placebo in retrograde cardioplegia
Number of subjects: 80
Study 19158228 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (PRO) with 1.6 g/kg/d protein and <170 g/d carbohydrates
Number of subjects: 130
Study 19158228 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (PRO)
Number of subjects: 130
Study 19158228 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-carbohydrate diet (CHO)
Number of subjects: 130
Study 17451579 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 U of BTX (BOTOX Cosmetic, Allergan Inc.)
Number of subjects: 20
Study 15169614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0
Study 15169614 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study 11289347 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch (200 kDa, 0.60‐0.66 substitution)
Number of subjects: 129
Study 11289347 — intervention group
Group type: COMPARATOR
Intervention: 3% fluid‐modified gelatin
Number of subjects: 129
Study 9923089 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-stimulated plasma CCK bioactivity in CP patients
Number of subjects: 24
Study 9923089 — intervention group
Group type: COMPARATOR
Intervention: Meal-stimulated plasma CCK bioactivity in healthy controls
Number of subjects: 24
Study 9923089 — intervention group
Group type: COMPARATOR
Intervention: Comparison of plasma CCK bioactivity between CP patients and healthy controls
Number of subjects: 24
Study 9923089 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between impairment of pancreatic exocrine function and plasma CCK bioactivity
Number of subjects: 24
Study 8149056 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (first postoperative day)
Number of subjects: 0
Study 8149056 — intervention group
Group type: COMPARATOR
Intervention: Late mobilisation (tenth postoperative day)
Number of subjects: 0
Study 8149056 — intervention group
Group type: EXPERIMENTAL
Intervention: History of oral steroid therapy
Number of subjects: 0
Study 8149056 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of tissue damage (undermining of skin margins, damage to fascia, exposure of periosteum)
Number of subjects: 0
Study 2905256 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg once daily
Number of subjects: 300
Study 2905256 — intervention group
Group type: COMPARATOR
Intervention: roxatidine acetate 75 mg twice daily
Number of subjects: 300
Study 29588293 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention assisted by a promotora (Hispanic community health worker)
Number of subjects: 251
Study 26695507 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced Caregivers Helping Others intervention
Number of subjects: 0
Study 26695507 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard inpatient care)
Number of subjects: 0
Study 25087325 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulation
Number of subjects: 213
Study 25087325 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led resuscitation training-only group
Number of subjects: 213
Study 23770179 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 40 mg
Number of subjects: 177
Study 23770179 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 80 mg
Number of subjects: 177
Study 23770179 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 120 mg
Number of subjects: 177
Study 23770179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 20185616 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours of robotic-assisted therapy combined with 30 hours of therapist-supervised repetitive task practice (RTP)
Number of subjects: 17
Study 20185616 — intervention group
Group type: COMPARATOR
Intervention: 60 hours of therapist-supervised repetitive task practice (RTP)
Number of subjects: 17
Study 20185616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined therapy and RTP-only)
Number of subjects: 17
Study 20185616 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group
Number of subjects: 17
Study 20185616 — intervention group
Group type: COMPARATOR
Intervention: RTP-only group
Number of subjects: 17
Study 18286595 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC) 20-50 mg/kg/day
Number of subjects: 63
Study 18286595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16422828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study 16422828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14583175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic treatment aiming at normal HbA1c levels
Number of subjects: 1700
Study 14583175 — intervention group
Group type: COMPARATOR
Intervention: Standard arm with usual, improved glycemic control
Number of subjects: 1700
Study 10555125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 without G-CSF
Number of subjects: 35
Study 10555125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 with G-CSF
Number of subjects: 35
Study 10555125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin pharmacokinetics
Number of subjects: 35
Study 10555125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2
Number of subjects: 35
Study 8724309 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin) at a dose between 1.5 and 2.0 g/kg/infusion (100 g maximum) bimonthly for the first 2 months, then monthly for up to 6 months
Number of subjects: 25
Study 8724309 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin) continued in the double-blind phase
Number of subjects: 25
Study 8724309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8724309 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin)
Number of subjects: 25
Study 1761450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin dosage regimens determined by a computerized pharmacokinetic predictive program (Group B)
Number of subjects: 0
Study 1761450 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin dosage regimens decided by clinicians based on pre-existing protocols (Group A)
Number of subjects: 0
Study 6750609 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia treatment (three 30-min insufflations of humidified air at 43 degrees C at a 2-hr interval)
Number of subjects: 95
Study 6750609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 95
Study 30070706 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution applied 4 times per day
Number of subjects: 10
Study 30070706 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution applied 8 times per day
Number of subjects: 10
Study 30070706 — intervention group
Group type: COMPARATOR
Intervention: Control group (0× sucrose treatment)
Number of subjects: 10
Study 27913933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Reduction Diet (FRD)
Number of subjects: 30
Study 27913933 — intervention group
Group type: COMPARATOR
Intervention: General Health Curriculum (GHC)
Number of subjects: 30
Study 26822022 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 12 weeks
Number of subjects: 50
Study 26822022 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 16 weeks
Number of subjects: 50
Study 26822022 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 12 weeks in patients with cirrhosis
Number of subjects: 50
Study 26822022 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 16 weeks in patients with cirrhosis
Number of subjects: 50
Study 26822022 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for treatment-experienced patients with cirrhosis
Number of subjects: 50
Study 25098442 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed Educational Materials (PEMs)
Number of subjects: 437
Study 25098442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 437
Study 22549401 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine training
Number of subjects: 115
Study 22549401 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training
Number of subjects: 115
Study 22549401 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented training
Number of subjects: 115
Study 22549401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing consultation after training
Number of subjects: 115
Study 19189088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of bromazepam
Number of subjects: 8
Study 19189088 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric administration of bromazepam
Number of subjects: 8
Study 19189088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of omeprazole
Number of subjects: 8
Study 19189088 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric administration of omeprazole
Number of subjects: 8
Study 19189088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of paracetamol
Number of subjects: 8
Study 19189088 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric administration of paracetamol
Number of subjects: 8
Study 17399725 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity inducing slopes 1000 m/s(3)
Number of subjects: 64
Study 17399725 — intervention group
Group type: EXPERIMENTAL
Intervention: Impacts with slopes <1000 m/s(3)
Number of subjects: 64
Study 17399725 — intervention group
Group type: EXPERIMENTAL
Intervention: Impacts with slopes 1500 m/s(3) or areas 4m/s
Number of subjects: 64
Study 15389347 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg once daily)
Number of subjects: 0
Study 15389347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11464229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification with increased use of vitamin E-rich foods
Number of subjects: 82
Study 11464229 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 200 IU of vitamin E
Number of subjects: 82
Study 11464229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 9882032 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg before breakfast (qAM)
Number of subjects: 18
Study 9882032 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg before dinner (qPM)
Number of subjects: 18
Study 9882032 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg before breakfast and dinner (b.d.)
Number of subjects: 18
Study 7924325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h
Number of subjects: 24
Study 7924325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 50 micrograms/24h
Number of subjects: 24
Study 7924325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 100 micrograms/24h
Number of subjects: 24
Study 7924325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG)
Number of subjects: 24
Study 7924325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) + estradiol (50 or 100 micrograms/24h)
Number of subjects: 24
Study 7924325 — intervention group
Group type: COMPARATOR
Intervention: Estradiol treatment
Number of subjects: 24
Study 2803900 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria/tetanus vaccine
Number of subjects: 180
Study 1169086 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (P.G.V.) without drainage
Number of subjects: 100
Study 1169086 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy and gastrojejunostomy
Number of subjects: 100
Study 1169086 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (P.G.V.) with gastrojejunostomy
Number of subjects: 100
Study 29035844 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 643
Study 29035844 — intervention group
Group type: COMPARATOR
Intervention: Guided femoral access (fluoroscopy, micropuncture, ultrasound)
Number of subjects: 643
Study 29035844 — intervention group
Group type: COMPARATOR
Intervention: Non-guided femoral access
Number of subjects: 643
Study 27875518 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced reminder letter
Number of subjects: 168480
Study 27875518 — intervention group
Group type: COMPARATOR
Intervention: Usual reminder letter
Number of subjects: 168480
Study 23835594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (alternating 60s at 100% VO(2peak) and 240s at 50% VO(2peak))
Number of subjects: 17
Study 23835594 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-intensity intermittent exercise (alternating 15s at 170% VO(2peak) and 60s at 32% VO(2peak))
Number of subjects: 17
Study 23835594 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-intensity intermittent exercise
Number of subjects: 17
Study 23835594 — intervention group
Group type: COMPARATOR
Intervention: High-intensity intermittent exercise and Very-high-intensity intermittent exercise
Number of subjects: 17
Study 20888653 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 602
Study 20888653 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 602
Study 20856152 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG‐PET
Number of subjects: 150
Study 20856152 — intervention group
Group type: COMPARATOR
Intervention: Conventional Work-Up (CWU)
Number of subjects: 150
Study 20856152 — intervention group
Group type: EXPERIMENTAL
Intervention: NMB analysis
Number of subjects: 150
Study 18818460 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus minocycline
Number of subjects: 30
Study 18818460 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 30